Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low-dose warfarin decreases coagulability without affecting prothrombin complex activity

J Holm1, E Berntorp, R Carlsson

  • 1Department of Medicine, Lund University, Malmö General Hospital, Sweden.

Journal of Internal Medicine
|September 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Fifth Åland Island conference on von Willebrand disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Replacement therapy during surgery in von Willebrand disease needs personalization.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Defining extended half-life rFVIII-A critical review of the evidence.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Immune tolerance induction: What have we learned over time?

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same journal

Patients with hereditary hemorrhagic telangiectasia have significantly reduced overall survival-And likely by a greater magnitude than we realize.

Journal of internal medicine·2026
Same journal

Social jet lag is associated with incident cardiovascular disease independent of sleep duration and cardiac genetic risk.

Journal of internal medicine·2026
Same journal

Multicenter validation of a severity index model for predicting postoperative acute kidney injury.

Journal of internal medicine·2026
Same journal

The changing epidemiology of human type 2 diabetes-associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities.

Journal of internal medicine·2026
Same journal

Angiopoietin-like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride-rich lipoproteins in humans.

Journal of internal medicine·2026
Same journal

Authors' reply: Myasthenia gravis following the initiation of statin therapy.

Journal of internal medicine·2026
See all related articles

Low-dose warfarin (1.25 mg/day) combined with aspirin demonstrated an anticoagulant effect by lowering factor VII coagulant activity (FVII:C) and thrombin formation. This regimen appears safe for arterial thrombotic disease without affecting protein C levels.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Hematology

Background:

  • Arterial thrombotic diseases remain a significant cause of morbidity and mortality.
  • Effective antithrombotic therapies are crucial for managing patients with a history of myocardial infarction.
  • Warfarin is a commonly used anticoagulant, but its optimal dosing for specific conditions is under investigation.

Purpose of the Study:

  • To evaluate the efficacy of a fixed, low dose of warfarin in reducing factor VII coagulant activity (FVII:C).
  • To assess the impact of low-dose warfarin on the plasma coagulation cascade.
  • To investigate the safety and practicality of low-dose warfarin combined with aspirin for arterial thrombotic disease.

Main Methods:

  • An open pilot study involving 12 male patients with a history of myocardial infarction.

Related Experiment Videos

  • Two warfarin dose levels (1.25 mg/day and 2.5 mg/day) were administered over consecutive 4-week periods, alongside daily aspirin (75 mg).
  • Key coagulation markers including FVII:C, prothrombin fragment 1 + 2 (F(1 + 2)), protein C, protein S, factor X, and prothrombin complex activity (P-PT) were measured.

    • Main Results:

    • Warfarin 1.25 mg/day significantly lowered FVII:C and F(1 + 2) (a marker of thrombin formation) without affecting protein C or P-PT.
    • The higher dose (2.5 mg/day) resulted in further reduction of FVII:C and also significantly decreased protein C and P-PT levels.
    • No significant changes in protein S or factor X were reported.

    Conclusions:

    • A low dose of warfarin (1.25 mg/day) exerts an anticoagulant effect, indicated by reduced FVII:C and thrombin generation, without compromising protein C levels or prothrombin time (PT).
    • This low-dose warfarin and aspirin combination is suggested as a safe and straightforward treatment for arterial thrombotic disease.
    • Regular PT monitoring may not be necessary with this specific low-dose regimen, simplifying patient management.